Inovio Pharmaceuticals Accused of Misleading Investors in Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy INO?
Source: PRnewswire
- Class Action Filed: Robbins LLP reminds shareholders that a class action has been initiated on behalf of all individuals who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, reflecting investor concerns about the company's future prospects.
- Regulatory Issues Uncovered: The lawsuit alleges that Inovio misled investors regarding deficiencies in the manufacturing of its CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, potentially impacting its market competitiveness and investor confidence.
- Stock Price Volatility: On August 8, 2024, Inovio reported a delay in submitting the BLA due to manufacturing issues, causing a 3.1% drop in stock price to $8.44; on December 29, 2025, the FDA accepted the application for standard review, leading to a further 24.45% decline to $1.73, indicating a pessimistic market sentiment.
- Call to Action for Shareholders: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 7, 2026, highlighting the importance of corporate governance and transparency, which may influence future investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.690
Low
3.00
Averages
7.33
High
13.00
Current: 1.690
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds shareholders that a class action has been initiated on behalf of all individuals who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, reflecting investor concerns about the company's future prospects.
- Regulatory Issues Uncovered: The lawsuit alleges that Inovio misled investors regarding deficiencies in the manufacturing of its CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, potentially impacting its market competitiveness and investor confidence.
- Stock Price Volatility: On August 8, 2024, Inovio reported a delay in submitting the BLA due to manufacturing issues, causing a 3.1% drop in stock price to $8.44; on December 29, 2025, the FDA accepted the application for standard review, leading to a further 24.45% decline to $1.73, indicating a pessimistic market sentiment.
- Call to Action for Shareholders: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 7, 2026, highlighting the importance of corporate governance and transparency, which may influence future investment decisions.
See More
Class Action Lawsuit Announced Against Inovio Pharmaceuticals
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Inovio Pharmaceuticals (NASDAQ:INO) securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock performance.
- Basis of the Lawsuit: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which delayed the submission of its INO-3107 Biologics License Application (BLA), thereby affecting the company's future regulatory and commercial prospects.
- Investor Losses: As the true details emerged, investors may have suffered damages, and the lawsuit provides an opportunity for affected investors to seek compensation without any out-of-pocket fees, highlighting the protective role of legal action for investor rights.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which underscores its strength and experience in handling similar cases, potentially boosting investor confidence in the lawsuit's outcome.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Inovio Pharmaceuticals and certain officers, seeking damages for investors who acquired Inovio securities between October 10, 2023, and December 26, 2025, highlighting significant investor concerns regarding corporate transparency.
- Allegations of False Statements: The complaint alleges that Inovio made materially false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device, leading to investor misconceptions about the regulatory and commercial prospects of INO-3107, which could impact future financing capabilities.
- Uncertain Regulatory Outlook: The lawsuit indicates that Inovio is unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024, suggesting significant delays in market access for a key product, which may adversely affect the company's stock price and market confidence.
- Investor Rights Protection: The law firm offers legal services on a contingency fee basis, meaning they will only charge fees after successfully recovering losses, demonstrating a commitment to protecting investor rights and interests.
See More
Inovio Pharmaceuticals Faces Class Action for Misleading Investors
- Lawsuit Background: Rosen Law Firm has initiated a class action lawsuit on behalf of investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, alleging misleading business operations that resulted in investor losses.
- Key Allegations: The lawsuit claims that throughout the class period, Inovio made false and/or misleading statements and failed to disclose deficiencies in the manufacturing of its CELLECTRA device, which hindered timely submission of the INO-3107 Biologics License Application to the FDA.
- Regulatory Prospects Damaged: Due to insufficient information to justify INO-3107's eligibility for FDA accelerated approval, the lawsuit asserts that Inovio's overall regulatory and commercial prospects were significantly overstated, impacting investor decision-making.
- Next Steps: Investors may apply to serve as lead plaintiffs in the class action by April 7, 2026, representing other members in directing the litigation, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: A securities class action lawsuit has been initiated in the U.S. District Court for the Eastern District of Pennsylvania against Inovio Pharmaceuticals, covering all investors who purchased the company's securities between October 10, 2023, and December 26, 2025, indicating significant investor dissatisfaction with the company's transparency.
- Allegations of Manufacturing Deficiencies: The complaint alleges that Inovio failed to disclose manufacturing deficiencies related to its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024, thereby impacting investor decision-making.
- Overstated Regulatory Prospects: The lawsuit further claims that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, suggesting that the company's regulatory and commercial prospects were significantly overstated, potentially leading to investor losses.
- Investor Rights Protection: Investors are encouraged to contact the law firm before the April 7, 2026, lead plaintiff motion deadline to protect their rights in the class action, highlighting the legal emphasis on safeguarding investor interests.
See More
Inovio Pharmaceuticals Faces Class Action for Investor Misleading
- Lawsuit Background: Robbins LLP has filed a class action against Inovio Pharmaceuticals, alleging that the company misled investors between October 10, 2023, and December 26, 2025, by failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the INO-3107 FDA submission.
- Regulatory Delays: The submission of the INO-3107 Biologics License Application (BLA), initially expected in the second half of 2024, has been postponed to mid-2025 due to manufacturing issues, resulting in a misjudgment of the company's prospects by investors and directly impacting stock prices.
- Stock Price Volatility: Following the financial report on August 8, 2024, which revealed the delay, Inovio's stock price fell by 3.1% to $8.44 per share; on December 29, 2025, after the FDA accepted the application for standard review, the stock plummeted by 24.45% to $1.73 per share.
- Investor Rights: Robbins LLP is urging affected shareholders to participate in the lawsuit, as lead plaintiffs in the class action, emphasizing that investors do not need to participate in the case to be eligible for recovery, highlighting the importance of corporate governance and shareholder rights.
See More
Inovio Pharmaceuticals Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds shareholders that a class action has been initiated on behalf of all individuals who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, reflecting investor concerns about the company's future prospects.
- Regulatory Issues Uncovered: The lawsuit alleges that Inovio misled investors regarding deficiencies in the manufacturing of its CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, potentially impacting its market competitiveness and investor confidence.
- Stock Price Volatility: On August 8, 2024, Inovio reported a delay in submitting the BLA due to manufacturing issues, causing a 3.1% drop in stock price to $8.44; on December 29, 2025, the FDA accepted the application for standard review, leading to a further 24.45% decline to $1.73, indicating a pessimistic market sentiment.
- Call to Action for Shareholders: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 7, 2026, highlighting the importance of corporate governance and transparency, which may influence future investment decisions.
See More
Class Action Lawsuit Announced Against Inovio Pharmaceuticals
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Inovio Pharmaceuticals (NASDAQ:INO) securities between October 10, 2023, and December 26, 2025, indicating significant legal risks that could impact the company's stock performance.
- Basis of the Lawsuit: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which delayed the submission of its INO-3107 Biologics License Application (BLA), thereby affecting the company's future regulatory and commercial prospects.
- Investor Losses: As the true details emerged, investors may have suffered damages, and the lawsuit provides an opportunity for affected investors to seek compensation without any out-of-pocket fees, highlighting the protective role of legal action for investor rights.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which underscores its strength and experience in handling similar cases, potentially boosting investor confidence in the lawsuit's outcome.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Inovio Pharmaceuticals and certain officers, seeking damages for investors who acquired Inovio securities between October 10, 2023, and December 26, 2025, highlighting significant investor concerns regarding corporate transparency.
- Allegations of False Statements: The complaint alleges that Inovio made materially false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device, leading to investor misconceptions about the regulatory and commercial prospects of INO-3107, which could impact future financing capabilities.
- Uncertain Regulatory Outlook: The lawsuit indicates that Inovio is unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024, suggesting significant delays in market access for a key product, which may adversely affect the company's stock price and market confidence.
- Investor Rights Protection: The law firm offers legal services on a contingency fee basis, meaning they will only charge fees after successfully recovering losses, demonstrating a commitment to protecting investor rights and interests.
See More
Inovio Pharmaceuticals Faces Class Action for Misleading Investors
- Lawsuit Background: Rosen Law Firm has initiated a class action lawsuit on behalf of investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, alleging misleading business operations that resulted in investor losses.
- Key Allegations: The lawsuit claims that throughout the class period, Inovio made false and/or misleading statements and failed to disclose deficiencies in the manufacturing of its CELLECTRA device, which hindered timely submission of the INO-3107 Biologics License Application to the FDA.
- Regulatory Prospects Damaged: Due to insufficient information to justify INO-3107's eligibility for FDA accelerated approval, the lawsuit asserts that Inovio's overall regulatory and commercial prospects were significantly overstated, impacting investor decision-making.
- Next Steps: Investors may apply to serve as lead plaintiffs in the class action by April 7, 2026, representing other members in directing the litigation, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: A securities class action lawsuit has been initiated in the U.S. District Court for the Eastern District of Pennsylvania against Inovio Pharmaceuticals, covering all investors who purchased the company's securities between October 10, 2023, and December 26, 2025, indicating significant investor dissatisfaction with the company's transparency.
- Allegations of Manufacturing Deficiencies: The complaint alleges that Inovio failed to disclose manufacturing deficiencies related to its CELLECTRA device, which diminishes the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024, thereby impacting investor decision-making.
- Overstated Regulatory Prospects: The lawsuit further claims that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, suggesting that the company's regulatory and commercial prospects were significantly overstated, potentially leading to investor losses.
- Investor Rights Protection: Investors are encouraged to contact the law firm before the April 7, 2026, lead plaintiff motion deadline to protect their rights in the class action, highlighting the legal emphasis on safeguarding investor interests.
See More
Inovio Pharmaceuticals Faces Class Action for Investor Misleading
- Lawsuit Background: Robbins LLP has filed a class action against Inovio Pharmaceuticals, alleging that the company misled investors between October 10, 2023, and December 26, 2025, by failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the INO-3107 FDA submission.
- Regulatory Delays: The submission of the INO-3107 Biologics License Application (BLA), initially expected in the second half of 2024, has been postponed to mid-2025 due to manufacturing issues, resulting in a misjudgment of the company's prospects by investors and directly impacting stock prices.
- Stock Price Volatility: Following the financial report on August 8, 2024, which revealed the delay, Inovio's stock price fell by 3.1% to $8.44 per share; on December 29, 2025, after the FDA accepted the application for standard review, the stock plummeted by 24.45% to $1.73 per share.
- Investor Rights: Robbins LLP is urging affected shareholders to participate in the lawsuit, as lead plaintiffs in the class action, emphasizing that investors do not need to participate in the case to be eligible for recovery, highlighting the importance of corporate governance and shareholder rights.
See More
